437 related articles for article (PubMed ID: 31111422)
1. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
3. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in Dermatology - theory becomes reality.
Gerdes S; Mrowietz U; Augustin M; Ralph von Kiedrowski ; Enk A; Strömer K; Schön MP; Radtke MA
J Dtsch Dermatol Ges; 2018 Feb; 16(2):150-160. PubMed ID: 29364594
[TBL] [Abstract][Full Text] [Related]
5. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
6. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System.
Jourdain H; Hoisnard L; Sbidian E; Zureik M
RMD Open; 2024 Mar; 10(1):. PubMed ID: 38453213
[TBL] [Abstract][Full Text] [Related]
7. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.
Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjöwall C; Lindqvist E; Askling J
Rheumatology (Oxford); 2022 Aug; 61(9):3596-3605. PubMed ID: 34919663
[TBL] [Abstract][Full Text] [Related]
8. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence studies with anti-TNF biosimilars.
Gimeno-Gracia M; Gargallo-Puyuelo CJ; Gomollón F
Expert Opin Biol Ther; 2019 Oct; 19(10):1031-1043. PubMed ID: 30574813
[No Abstract] [Full Text] [Related]
10. Biosimilars for the treatment of psoriatic arthritis.
Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
[No Abstract] [Full Text] [Related]
11. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.
Jacobs I; Petersel D; Isakov L; Lula S; Lea Sewell K
BioDrugs; 2016 Dec; 30(6):525-570. PubMed ID: 27885553
[TBL] [Abstract][Full Text] [Related]
13. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
Zhao S; Chadwick L; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
[TBL] [Abstract][Full Text] [Related]
14. Risk Assessment and Monitoring of Antibody Responses to Biosimilars in Chronic Inflammatory Diseases.
Detrez I; Gils A
Curr Pharm Des; 2017; 23(44):6739-6745. PubMed ID: 29189133
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe.
Agboton C; Salameh J
Expert Opin Biol Ther; 2022 Feb; 22(2):157-167. PubMed ID: 34338115
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
Solitano V; D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
Expert Rev Clin Immunol; 2020 Oct; 16(10):1019-1028. PubMed ID: 32954893
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars in inflammatory bowel disease: A review of post-marketing experience.
Deiana S; Gabbani T; Annese V
World J Gastroenterol; 2017 Jan; 23(2):197-203. PubMed ID: 28127193
[TBL] [Abstract][Full Text] [Related]
19. A review of biosimilars for rheumatoid arthritis.
Conran CA; Moreland LW
Curr Opin Pharmacol; 2022 Jun; 64():102234. PubMed ID: 35552095
[TBL] [Abstract][Full Text] [Related]
20. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals.
Jarrion Q; Azzouz B; Robinson J; Jolly D; Vallet C; Trenque T
Therapie; 2022; 77(4):467-475. PubMed ID: 35027238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
